US FDA hits Salix with complete response letter for Giazo
This article was originally published in Scrip
Executive Summary
Salix Pharmaceuticals has received a US FDA complete response letter for Giazo (balsalazide 1.1g tablets), its oral anti-inflammatory candidate for mild-to-moderate ulcerative colitis.